Page results
-
Macmillan Support and Information Service offer emotional support, advice and information to people affected by cancer and blood conditions.
-
UCLH is one of the largest blood cancers treatment centres in Europe, with both inpatient beds and a comprehensive day care service. The service is the main treatment centre for patients from north and east London, and west Essex.
-
This page has been written for patients having proton beam therapy (PBT) at University College Hospital (UCH).
-
Our new report shows the difference charitable funds can make to patients, staff and research at UCLH
-
This service is unique in the UK, offering an adolescent rheumatology service that provides diagnostic and therapeutic advice to patients with any rheumatic diseases that occur in adolescence.
-
The Bidborough House NHS Vaccination Centre has now closed.
-
This page provides an overview of our Teenage and Young Adult (TYA) Ambulatory Care Service available to patients aged 12 to 24 years.
-
After almost six months and more than 120,000 vaccinations the Islington Business Design Centre closes as a vaccination centre today (20 August 2021).
-
This page contains information for patients (and their family and carers) who are considering having ablation for a liver tumour.
-
UCLH works in partnership with GPs in Barnet and Enfield to provide a community based ear, nose and throat (ENT) service. The Community ENT service provides specialist advice and treatment for a range of minor ENT conditions.
File results
-
FOI/2023/0550 - Varicose veins referrals, treatment and wait time
-
FOI/2023/0553 - Maternity complaints by ethnicity
-
FOI/2023/0559 - Patients admitted to hospital with dental distress
-
FOI/2023/0560 - Digital maternity training platform
-
FOI/2023/0561 - Birthrate Plus
-
FOI/2023/0563 - Treatment for Haemophilia B and Von Willebrand disease
-
FOI/2023/0565 - Rare diseases - diagnosis/ treatment for Fabry/ Gaucher/ Pompe
-
FOI/2023/0566 - Structure chart for IM &T, Business Intelligence, Informatics
-
FOI/2023/0569 - Treatment for Ruxolitinib
-
FOI/2023/0578 - Spinal Muscular Atrophy (SMA) patients